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Remodeling of the tricarboxylic acid (TCA) cycle
is a metabolic adaptation accompanying inflam-
matory macrophage activation. During this pro-
cess, endogenous metabolites can adopt regu-
latory roles that govern specific aspects of
inflammatory response, as recently shown for
succinate, which regulates the pro-inflammatory
IL-1b-HIF-1a axis. Itaconate is one of the most
highly induced metabolites in activated macro-
phages, yet its functional significance remains un-
known. Here, we show that itaconate modulates
macrophage metabolism and effector functions
by inhibiting succinate dehydrogenase-mediated
oxidation of succinate. Through this action, itaco-
nate exerts anti-inflammatory effects when admin-
istered in vitro and in vivo during macrophage
activation and ischemia-reperfusion injury. Using
newly generated Irg1/ mice, which lack the
ability to produce itaconate, we show that endoge-
nous itaconate regulates succinate levels and
function, mitochondrial respiration, and inflamma-
tory cytokine production during macrophage
activation. These studies highlight itaconate as a
major physiological regulator of the global meta-
bolic rewiring and effector functions of inflamma-
tory macrophages.158 Cell Metabolism 24, 158–166, July 12, 2016 ª 2016 Elsevier Inc.INTRODUCTION
Macrophage activation by lipopolysaccharide (LPS) is accompa-
nied by marked metabolic changes including upregulation of aer-
obic glycolysis (Everts et al., 2014), impaired mitochondrial respi-
ration, disruption of the TCA cycle (Jha et al., 2015), and
accumulation of succinate (Kelly andO’Neill, 2015).While a signif-
icant portion of this metabolic adaptation is transcriptionally
controlled (e.g., via modulation ofNos2 andCox2), succinate rep-
resentsanexampleofametabolite thataffectsmajor inflammatory
pathways in both immune and non-immune cells by controlling
IL-1b expression, HIF-1a activity, and ROS production (Kelly and
O’Neill, 2015). However, the mechanism(s) regulating succinate
levels in inflammatory macrophages have remained unknown.
Itaconate has been recently shown to be made by macro-
phages in response to LPS (Strelko et al., 2011) and certain in-
fections (Michelucci et al., 2013) and is generated by the
mitochondria-associated enzyme (Degrandi et al., 2009) immune
responsive gene 1 (Irg1). Itaconate is believed to have anti-bac-
terial function due to its ability to inhibit isocitrate lyase, a bacte-
rial glyoxylate shunt enzyme and due to its bactericidal effect
when added at supraphysiological concentrations to macro-
phage-free S. enterica, M. tuberculosis, and L. pneumonophilia
cultures (Michelucci et al., 2013) (Naujoks et al., 2016). An effect
of itaconate on mammalian enzymes also was reported in
the context of Sdh inhibition (Ackermann and Potter, 1949)
(Ne´meth et al., 2016). It is unknown, however, whether this
biochemical effect of itaconate translates into macrophage
metabolism and function. Here, using exogenous itaconate as
well as newly generated Irg1/ mice, we report that itaconate
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Figure 1. Itaconate Has Anti-inflammatory Effects on Macrophage Activation
(A) Volcano plots showing transcripts (left) and metabolites (right) that are differentially expressed between resting and activated BMDM (LPS + IFN-g, 24 hr).
(B) Relative expression of intracellular and secreted itaconate by BMDM at indicated time points after activation (LPS + IFN-g).
(C) Histogram of intracellular iNOS expression determined by flow cytometry in BMDMuntreated or DI-pretreated (0.25mM, 12 hr) and then stimulated with LPS +
IFN-g (24 hr).
(D) IL-12 levels in BMDM culture supernatants from (C).
(E) IL-6 and TNF-a secreted by untreated or DI-pretreated BMDM and stimulated with LPS (24 hr).
(F) Heatmap of selected inflammatory marker genes unstimulated (Uns), LPS-stimulated (LPS), DI-pretreated (DI + Uns), DI-pretreated and then LPS-stimulated
BMDM (4 hr).
(G) Mature IL-1b and IL-18 secreted by BMDM untreated or DI-pretreated, then stimulated with LPS (4 hr) and ATP (45 min).
(H) Mature IL-1b levels secreted by BMDM untreated or DI-pretreated and stimulated with LPS and nigericin (Nig.) or monosodium urate crystals (MSU).
(I) Western blot analysis of NLRP3, pro-IL-1b, and ASC in lysates of BMDM untreated or DI-pretreated and stimulated as in (G). a-tubulin was used as loading
control. Blot shown is representative of two independent experiments.
For (B), (E), (G), and (H), data are shown asmean ± SEM (n = 3). p values were calculated using two-tailed Student’s t test (B and E) or one-way ANOVA compared
to untreated stimulated cells (G and H). *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. See also Figure S1.potently modulates macrophage activation and inflammatory re-
sponses by controlling TCA cycle remodeling.
RESULTS AND DISCUSSION
Itaconate Treatment Has Anti-inflammatory Effects
during Macrophage Activation
Itaconate production is one of the hallmarks of macrophage acti-
vation onboth the transcriptional andmetabolic levels: Irg1 is oneof the most highly induced enzymes in activated macrophages,
and itaconate accumulates at high levels within cells (Figure 1A).
Metabolomic profiling of culture supernatants from activated
bone marrow-derived macrophages (BMDMs) revealed that
itaconate was also secreted, as suggested previously (Strelko
et al., 2011) (Figure 1B). The magnitude of itaconate production
prompted us to investigate its potential regulatory role.
We first tested the effect of exogenously added itaconate on
the inflammatory response induced after LPS or LPS + IFN-gCell Metabolism 24, 158–166, July 12, 2016 159
stimulation. We treated mouse BMDM with physiologically rele-
vant doses of dimethyl itaconate (DI) (Figure S1A), a membrane-
permeable non-ionic form of itaconate. Pretreatment with DI
suppressed iNOS protein expression (Figure 1C) and IL-12p70
and IL-6 secretion (Figures 1D and 1E), thereby interfering
with activation of pro-inflammatory macrophages. In contrast,
TNF-a levels remained unchanged (Figure 1E), indicating that
the effects of DI-treatment were not due to global inhibition of
NF-kB-dependent gene expression. To determine the specific
pathways affected by itaconate, we performed global transcrip-
tional profiling by RNA-seq on BMDM pretreated with DI or
vehicle and then stimulated with LPS. Differential gene expres-
sion confirmed that DI-treatment led to downregulation of a
spectrum of pro-inflammatory transcripts (Figures 1F and
S1B), including Nos2, Il6, and Il12b.
The RNA-seq analysis also revealed that DI-pretreatment
modulated the expression of several LPS-regulated genes
involved in inflammasome activation and function (Figure 1F),
including Il1b, Il18, P2rx7, Casp1, and Pycard (ASC). Indeed,
DI potently inhibited production of mature IL-1b and IL-18 in-
duced under prototypical NLRP3-activating conditions, namely
LPS-driven priming (signal 1) followed by signal 2 inducers
ATP, nigericin, and monosodium urate crystals (Figures 1G and
1H), whereas it affected inflammasome-induced cytotoxicity
only moderately (Figure S1C). DI-treated BMDM also had
impaired IL-1b production upon AIM-2-dependent inflamma-
some activation (Figure S1D), suggesting a broader regulatory
effect on the inflammasome. The decreased protein expression
of pro-IL-1b, ASC, and NLRP3 in DI-treated cells (Figure 1I) indi-
cated that itaconate-mediated inhibition of inflammasome func-
tion was due primarily to a defective priming phase.
In view of this anti-inflammatory action of itaconate, and given
its known cidal ability on extracellular bacteria, we next deter-
mined its effect on intracellular bacteria during macrophage
infection. To this end, we infected BMDMswithSalmonella typhi-
murium, an intracellular Gram-negative bacterium that triggers
TLR4 signaling and NLRP3 inflammasome activation (Broz
et al., 2010) in the presence or absence of DI pretreatment.
Consistent with our previous findings, infection-induced IL-1b,
IL-6, and nitric oxide (NO), but not TNF-a, were abrogated in
DI-treated cells (Figure S1E), whereas the number of intracellular
bacteria was comparable between DI-treated and control
BMDM (Figure S1F), indicating that the anti-inflammatory effects
of itaconate at non-cytotoxic concentrations did not result from
direct bactericidal activity. Rather, itaconate likely has a regula-
tory role, as supported by Irg1 induction in the viral infection
context (Cho et al., 2013) (Figure S1G), indicating it has regula-
tory functions that are not specific to anti-bacterial response.
Exogenous Itaconate Inhibits Succinate Dehydrogenase
In Vitro and In Vivo
As perturbations in cellular metabolism can lead to transcrip-
tional defects in IL-1b production and inflammasome activation
(Moon et al., 2015), we hypothesized that itaconate exerts its
anti-inflammatory action, in part, by interfering with cellular
metabolism. Using computational analysis of transcriptional
data (Becker and Palsson, 2008), we investigated the possible
rewiring of the metabolic flux triggered by itaconate in the
absence of LPS. Using a flux balance analysis framework, we160 Cell Metabolism 24, 158–166, July 12, 2016extended the metabolic model originally formulated for RAW
264.7 macrophage cell line (Bordbar et al., 2012) by including
several reactions and enzymes that were absent in the original
model (e.g., Irg1 and itaconate, see Experimental Procedures
for details). We searched for fluxes in untreated and itaconate-
treated conditions that were most consistent with the RNA-seq
data (see Experimental Procedures). A comparative network
highlights three types of metabolic flux change in response to
itaconate treatment (Figures 2A and S2A): decreased metabolic
flux (blue edges), increased metabolic flux (red), and reactions
insensitive to itaconate addition (gray).
Two features of the computational analysis were apparent.
First, itaconate addition was predicted to increase lactate dehy-
drogenase (Ldh) production. We confirmed this experimentally
using Seahorse technology on unstimulated BMDM with and
without DI treatment. We observed that extracellular acidifica-
tion rate (ECAR), which occurs as a consequence of lactate
accumulation in the medium, was increased in the presence of
itaconate (Figure 2B). The second prediction was that itaconate
addition should decrease the metabolic flux through Sdh. This
suggested that itaconate might inhibit Sdh competitively,
conceivably due the structural similarity between itaconate, suc-
cinate, andmalonate, the latter a knownSdh inhibitor (Figure 2C).
Indeed, 67 years ago, an inhibitory effect of itaconate on Sdh
was postulated based on similar effects of malonate and itaco-
nate on mitochondria function (Ackermann and Potter, 1949).
To evaluate this hypothesis, we compared the activity of purified
Sdh in the presence or absence of itaconate. Notably, itaconate
dose-dependently blocked the activity of Sdh when succinate
was used near physiological concentration 1 mM (Bennett
et al., 2009) (Figure S2B), and itaconate treatment of resting
BMDM led to increased succinate levels (Figure 2D). Kinetic
analysis confirmed the competitive mode of inhibition of Sdh
by itaconate (Figure 2E, left), and Dixon plot analysis showed
Ki for itaconate 0.22 mM (Figure 2E, right). The calculated Km
value for succinate was 0.29 ± 0.8 mM. These results are in
line with the molar amounts of intracellular succinate and itaco-
nate present in LPS-activated macrophages at 24 hr (Fig-
ure S2C). These data suggest that the anti-inflammatory effects
of itaconate in BMDM were likely due to inhibition of Sdh.
Supporting this notion, pretreatment with dimethyl malonate
also inhibited IL-1b production after LPS + ATP stimulation
(Figure S2D).
We next evaluated whether itaconate inhibits Sdh activity
in vivo. A recent study (Chouchani et al., 2014) highlighted the
proinflammatory role of succinate oxidation in the context of car-
diac ischemia-reperfusion (IR) injury. mROS generation during IR
injury was proposed to occur in the mitochondria as a result of
reverse electron transport (RET), whereby Sdh was fueled by
the succinate that accumulated during ischemia. Accordingly,
inhibition of Sdh by dimethyl malonate limited IR injury and
mROS levels (Chouchani et al., 2014). We used this model to
test whether itaconate would inhibit Sdh-mediated oxidation
in vivo. Intravenous infusion of DI during ischemia markedly
reduced myocardial infarct size (Figures 2F and 2G). While the
area-at-risk was similar between the two groups (Figure 2H),
the 42% reduction in infarct size with DI treatment was compa-
rable to that seen after dimethyl malonate administration (Chou-
chani et al., 2014), suggesting a common mechanism of action.
Figure 2. Itaconate Inhibits Sdh Activity In Vitro and In Vivo and Modulates ROS-Mediated Tissue Damage during Ischemia-Reperfusion
Injury
(A) Comparative network showing changes in the magnitude of predicted fluxes between unstimulated macrophages with and without itaconate treatment.
(B) Extracellular acidification rate (ECAR) measured in DI-treated or untreated BMDM. Data are shown as mean ± SEM of 10–15 replicates from one of two
representative experiments.
(C) Chemical structure of succinate, malonate, and itaconate.
(D) Relative succinate levels in resting BMDM treated or not with DI. Data are shown as mean ± SEM (n = 3). p values were calculated using two-tailed Student’s
t test.
(E) Lineweaver-Burk plot (left), Dixon plot (right), and calculated Km and Ki values. Data shown are mean ± SD (L-B plot, n = 3) and mean (Dixon plot, n = 3).
(F) Representative Evans Blue and TTC stained sections of hearts subjected to IR injury, after DI or saline treatment.
(G and H) Quantitation of area-at-risk (AAR) and infarct area (IA) as percent of AAR (G) and left ventricular (LV) myocardium (H) (saline, n = 8; DI, n = 7). p values
were calculated using two-tailed Student’s t test.
(I) Percentage change in ROS (over respective normoxic controls) in neonatal rat cardiacmyocytes (NRCMs) subjected to hypoxia for 24 hr in the presence of DI or
diluent.
(J) Percentage of cell death in NRCMs treated as in (H). For (I) and (J), p values were calculated using post hoc test after one-way ANOVA (n = 8/ condition).
(K) Histograms of mROS expression detected using MitoSox dye in BMDM pretreated or not with DI and activated with LPS (3 hr).
(L) Fold change in mROS mean fluorescence intensity (relative to medium) measured in (K).
Data are shown as mean ± SEM (n = 3, each in duplicates). p value was calculated using two-tailed Student’s t test. *p < 0.05; **p < 0.01; ***p < 0.001. See also
Figure S2.To evaluate this hypothesis, we used an in vitro assay that
mimics myocardial infarction injury by subjecting neonatal cardi-
omyocytes to hypoxic insult (Ma et al., 2012). Pretreatment with
DI attenuated the hypoxia-induced increase in ROS generation(Figure 2I) and conferred dose-dependent protection from hyp-
oxia-induced cell death (Figure 2J).
Therefore, we assessed whether itaconate-mediated Sdh
inhibition influenced mROS generation. Pretreatment with DICell Metabolism 24, 158–166, July 12, 2016 161
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*p < 0.05; ***p < 0.001; ****p < 0.0001. See also
Figure S3.impaired the ability of BMDM to upregulate mROS in response to
LPS (Figures 2K and 2L). As interfering with mROS can affect in-
flammasome priming (Bauernfeind et al., 2011), the blunted
mROS response mechanistically links Sdh inhibition and the
anti-inflammatory effects of itaconate on IL-1b and IL-18 pro-
duction (Figure 1G). Furthermore, it suggests that succinate
processing rather than accumulation is important for the inflam-
matory rewiring of macrophages.
Endogenous Itaconate Regulates Metabolic
Remodeling, Succinate Levels, and Mitochondrial
Respiration in Inflammatory Macrophages
To test the physiological relevance of endogenous itaconate, we
generated mice with a targeted disruption of the Irg1 gene (Fig-
ure S3). As BMDMs from Irg1/ mice failed to produce or
secrete itaconate (Figure 3A) after stimulation with LPS and
IFN-g, we conclude that Irg1 is the only enzyme carrying out itac-
onate synthesis under these conditions. LPS-activatedWTmac-
rophages show increased concentration of fumarate and malate162 Cell Metabolism 24, 158–166, July 12, 2016due to an active aspartate-argininosucci-
nate shunt (Jha et al., 2015), as well as
accumulation of succinate, presumably
due to itaconate inhibition. To confirm
this, we metabolically profiled Irg1/
BMDMs and observed marked changes
indicative of altered Sdh activity. Lack
of Irg1 expression led to abrogation of suc-
cinate accumulation, whereas fumarate
and malate concentrations were yet in-
creased (Figure 3B). Thus, in the absence
of endogenous itaconate, Sdh remained
active and oxidized succinate to fumarate,
which was rapidly converted to malate
(Figure 3C).
Besides its role in the TCA cycle, Sdh is
also part (as complex II) of the mitochon-
drial electron transport system. In LPS-
activated macrophages, mitochondrial
respiration decreases significantly (Kelly
andO’Neill, 2015). Thus, we testedwhether
itaconate-mediated inhibition of Sdh influ-enced mitochondrial function by measuring oxygen consump-
tion rates (OCR). Remarkably, contrary to WT cells, Irg1/
BMDMs showed increased OCR at 24 hr post activation
(Figure 3D), demonstrating that, by inhibiting Sdh, endogenous
itaconate modulates mitochondrial respiration, as recently pro-
posed for exogenous itaconate (Ne´meth et al., 2016).
Endogenous Itaconate Regulates Macrophage
Inflammatory Responses
We next assessed macrophage activation in the absence of
endogenous itaconate. We used RNA-seq to profile differences
in gene expression of LPS-activated wild-type (WT) and Irg1/
BMDMs. Notably, the transcriptional signature in Irg1/ cells
was essentially inversely correlated with itaconate-treated WT
cells: genes upregulated in Irg1/ cells were downregulated in
itaconate-treated WT BMDMs (Figure 4A), providing additional
evidence that endogenous itaconate functions in a manner
similar to exogenously added DI. Consistent with these observa-
tions, LPS-activated Irg1/ BMDM produced more IL-12, NO,
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and IL-6, but similar amounts of TNF-a, compared to WT cells
(Figures 4B and 4C). Irg1/ BMDM also sustained higher
expression of mature IL-1b and IL-18 under conditions that stim-
ulate NLPR3 (Figure 4D). Consistent with the known IL-1b-pro-
moting effect of HIF-1a (Tannahill et al., 2013), we observed
increased HIF-1a mRNA and protein levels in Irg1/ cells and,
reciprocally, suppression of HIF-1a expression in DI-treated
BMDM (Figures 4E–4G). Thus, changes in HIF-1a and IL-1b pro-
duction correlate with efficiency of succinate oxidation by Sdh.
These observations raise the possibility that the HIF-1a-IL-1b
axis is linked to the efficiency and directionality of the electron
transport chain in activated macrophages rather than direct
signaling through succinate accumulation.
In summary, our work identifies itaconate as part of a posttran-
scriptional mechanism that governs TCA cycle remodeling and
macrophage activation via its inhibitory effect on Sdh and regu-
lation of succinate levels. Our results expand the physiological
roles of itaconate beyond a direct anti-bacterial action, to include
regulation of TLR-mediated inflammatory cytokine production,
and provide a physiological regulatory mechanism to control
electron transport chain flow, succinate levels, ROS production,
and tissue inflammation.
EXPERIMENTAL PROCEDURES
Mice
Irg1/ (MGI:103206) mice were generated at Washington University after
receiving embryonic stem cells (ESCs) (Irg1tm1a(KOMP)Wtsi) from the Knockout
Mouse Project Repository (KOMP, University of California, Davis) containing
an insertion cassette between exons 3 and 4. This cassette prevents transcrip-
tion of downstream exons 4 and 5 and production of mature protein. Irg1/
C57BL/6N ESCs were microinjected into (Cg)-Tyrc-2J/J albino recipient
female C57BL/6 mouse blastocysts. Chimeric mice with black coat color
were selected and bred to wild-type C57BL/6N mice. Homozygous Irg1/
mice were generated by intercrossing the heterozygous animals and
confirmed by PCR. Irg1/ mice were fertile and exhibited normal Mendelian
frequencies, and BMDM from both sexes were used.
C57BL/6N WT mice from Charles River Laboratories were used as age-
matched controls. Mice were maintained at Washington University under spe-
cific pathogen-free conditions in accordance with Federal and University
guidelines and protocols approved by the Animal Studies Committee of Wash-
ington University.
Differentiation and Activation of Macrophages
BMDM were prepared from 6- to 8-week-old mice as described (Jha et al.,
2015) and seeded at 105 cells/well in 96-well tissue-culture plates in RMPI-
1640medium (ThermoFisher) supplementedwith 10%FBS, 2mML-glutamine
(Thermo Fisher Scientific), and 100 U/mL penicillin-streptomycin (Thermo
Fisher Scientific). Cells were treated or not with DI (0.25 mM, 12 hr; Sigma)
and activated as shown with LPS (E. coli 0111:B4; 100 ng/mL; Sigma) ±
IFNg (50 ng/mL; Peprotech). For inflammasome activation, cells were primed
with LPS (100 ng/mL, 4 hr) before addition of ATP (3mM, 45min; Sigma), niger-
icin (5 mM; 1 hr; Sigma) or monosodium urate crystals (250 mg/mL; 4 hr;
InvivoGen).
Flow Cytometry
Cells were incubated with anti-CD16/32 (clone 93, Biolegend), surface
stained for F4/80 (clone BM8, eBioscience) and CD11b (clone M1/70; BD
PharMingen) together with LIVE/DEAD dye (Invitrogen), followed by intracel-
lular iNOS stain with anti-NOS2 (clone C-11; Santa Cruz Biotechnology) and
FITC-conjugated IgG (Clone A85-1; BD PharMingen) using the BD cytofix/
cytopermKit (BD Biosciences). Cells were acquired on Canto II flow cytometer
(BD Biosciences), and data were analyzed with FlowJo v.9.5.2 software (Tree
Star).164 Cell Metabolism 24, 158–166, July 12, 2016Quantification of Cytokines and Nitric Oxide
Cytokines were quantified using DuoSet kits for IL-1b/IL-1F2, TNF-a, and IL-6
(all R&D systems), IL-12 ELISA MAX Deluxe Set (BioLegend), and IL-18 ELISA
kit (Medical & Biological Laboratories). Nitric oxide was detected with Griess
Reagent System (Promega).
Western Blotting
Cells were lysed in RIPA Lysis Buffer (Santa Cruz) and heat-denatured in
reducing sample buffer (Thermo Fisher Scientific). Proteins were separated
on 4%–20% polyacrylamide gradient gels (BioRad) and transferred onto
PVDF membranes. Non-specific binding was blocked with 5% skim milk,
and membranes were probed with primary antibodies to IL-1b (1:1,000;
12507S, Cell Signaling), Nlrp3 (1:500; NBP2-12446, Novus), HIF-1a (1:500;
NB100-449, Novus), a-tubulin (1:2,000; 2125S, Cell Signaling), and ASC
(1:1,000; sc-22514-R, Santa Cruz), followed by incubation with anti-rabbit-
HRP (1:10,000; sc-2030, Santa Cruz) and Clarity western ECL substrate
(Bio-Rad).
Sdh Activity Assay
Sdh was purified from the BV2 macrophage cell line and its activity measured
in the presence of itaconate using the Complex II Enzyme Activity Microplate
Assay Kit (Abcam) as per manufacturer’s protocol. Substrates were diluted in
activity buffer and added to the phospholipid mixture 5 min before adding the
activity solution. For kinetic analysis, sodium succinate hexahydrate was used
as indicated in activity buffer.
Extracellular Flux Analysis
Real-time extracellular acidification and oxygen consumption rates were
measured using Seahorse technology as described (Huang et al., 2014).
Metabolite Profiling by GC-MS
Cellular metabolites were extracted from an equal number of cells per sample
and analyzed by GC-MS as described (Vincent et al., 2015). Briefly, intracel-
lular metabolism was quenched with 800 ml of 80% methanol. To analyze
secreted metabolites, 20 ml supernatants were added to 800 ml of 80%
methanol. D-myristic acid (750 ng/sample) was used as internal standard.
Extracts were dried by vacuum centrifuge and pellets resuspended in 30 ml
pyridine-containing 10 mg/mL methoxyamine hydrochloride, before being de-
rivatized using N-(tert-butyldimethylsilyl)-N-methyltrifluoroacetamide. Metab-
olite abundance was expressed relative to the internal standard.
RNA-Seq Analysis
mRNA was extracted with oligo-dT beads (Invitrogen), and libraries were pre-
pared and quantified as described (Vincent et al., 2015).
Flux Balance Analysis
To investigate possible rewiring of the metabolic fluxes, we used flux balance
analysis framework (FBA). Using the RAW 264.7 macrophage cell line meta-
bolic model (Bordbar et al., 2012) and an algorithm similar to GIMME (Becker
and Palsson, 2008) and MADE (Jensen and Papin, 2011), we simulated fluxes
in untreated and DI-treated conditions based on their consistency with the
RNA-seq data for each condition. See Supplemental Information for detailed
analysis.
Myocardial Ischemia-Reperfusion Model
In vivo ischemia-reperfusion modeling was done as described (Ma et al.,
2012). 8- to 10-week-old mice were anesthetized and subjected to open chest
procedure of reversible left anterior descending artery ligation for 30 min and
subsequent reperfusion for 2 hr. Saline or DI (4 mg/kg/min) was infused intra-
venously 10 min before and during ischemia. A cardioplegic solution followed
by Evans Blue (after reocclusion of the LAD) was injected in a retrograde
manner through the aorta in situ. The left ventricle was then sectioned into
five slices, incubated in TTC (triphenyltetrazolium chloride) at 37C (30 min),
and images analyzed with ImageJ (NIH).
Hypoxia Modeling in Neonatal Rat Cardiac Myocytes
Neonatal rat cardiac myocytes were isolated and cultured as described (Ma
et al., 2012). Cells were subjected to hypoxia in an oxygen control cabinet
(Coy Laboratories) mounted within an incubator and equipped with oxygen
controller and sensor for continuous oxygen level monitoring. A mixture of
95% nitrogen and 5% CO2 was utilized to create hypoxia, and oxygen levels
in the chamber were monitored and maintained at <1%. Cell death was as-
sessed with the Live-Dead Cytotoxicity Viability kit for Mammalian cells
(Invitrogen) and ROS detected by flow cytometry with fluorescent carboxy-
H2DCFDA (after incubation in 10 mmol/L for 30 min) (Ma et al., 2012).
mROS Measurement
Cells were treated with DI (0.25 mM, 12 hr) or vehicle, loaded with 5 mM
MitoSOX (Invitrogen) at 37C for 30 min in HBSS supplemented with 0.1%
BSA, and rinsed with warm culture medium, before stimulation with LPS 1 hr
later (for 3 hr) and analysis on Canto II flow cytometer (Becton Dickinson).
Statistical Analysis
Statistical analyses were performed in GraphPad Prism 6 software using sta-
tistical tests indicated for each experiment.
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